Edge Therapeutics (EDGE) Says DMC Recommended Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage be Stopped
Tweet Send to a Friend
Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced that a pre-specified interim analysis performed on data from the Day 90 visit ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
